News: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

107.77USD
31 Oct 2014
Price Change (% chg)

$0.73 (+0.68%)
Prev Close
$107.04
Open
$108.00
Day's High
$108.18
Day's Low
$107.41
Volume
401,484
Avg. Vol
2,182,618
52-wk High
$108.77
52-wk Low
$86.09

Search Stocks
Select another date:

Wed, Oct 29 2014

INDIA PRESS-Johnson & Johnson may buy electrolyte drink ORS-L for 7 bln rupees - Times of India

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

NORDIC STOCKS - Factors to watch on Oct 24

OSLO, Oct 24 - The following stocks may be affected by newspaper reports and other factors on Friday:

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK/DALLAS - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.

UPDATE 2-Johnson & Johnson's DePuy wins first trial over Pinnacle hips

(Rewrites throughout, adds trial background and plaintiffs' lawyer quote, adds Dallas dateline)

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK, Oct 23 - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopaedics unit were defective.

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON, Oct 22 - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

J&J and Bavarian Nordic expand production of an Ebola vaccine program

- Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

J&J and Bavarian Nordic expand production of an Ebola vaccine program

Oct 22 - Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

Jury deliberations begin in first trial over DePuy's Pinnacle hips

- A lawyer for a Montana woman on Tuesday urged jurors in a U.S. court to find Johnson & Johnson's DePuy Orthopedics unit liable for failing to warn patients that metal-on-metal Pinnacle hip implants were defective at the close of the first trial over the device.

Select another date:
Search Stocks